Demetra Holding Spa Acquires Majority Stake in Swiss-based GetSet Surgical, Expanding Strategic Portfolio in the Spine Sector
Demetra Holding, an innovative and independent international medical company leader in providing anti-infective cements, spacers and biomaterials for orthopedic applications, today announced its acquisition of a 51% stake in GetSet Surgical, a leading Swiss-based spine surgical solutions provider.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227359973/en/
Michele Perrino, CEO of Demetra Holding (Photo: Business Wire)
The acquisition marks a significant step in Demetra Holding's strategy to broaden its offerings in the Spine sector. The collaboration will combine Demetra’s existing technologies with GetSet’s expertise in sterile spine procedure kits, creating a comprehensive spinal/orthopedic product lineup designed to reduce infection risks, optimize hospital efficiency and contribute to environment sustainability.
Strategic benefits of the acquisition
This investment will integrate the strengths of both companies, establishing a new approach to spine and orthopedic procedures. The use of sterile-packaged disposable implants and instruments helps to reduce the risk of infections and hospital costs associated with central sterilization issues, aligning directly with Demetra’s mission of becoming the company of choice for infection management and efficiency through its portfolio companies: Tecres, OSARTIS, OsteoRemedies and Yijiutai.
As a result of this acquisition, both companies will be able to offer integrated solutions that promote patient safety and operational efficiency, as well as environment sustainability, key objectives in modern healthcare.
Michele Perrino, CEO of Demetra Holding, commented: “Demetra Holding is proud to spearhead this collaboration, as it aligns perfectly with our mission to enhance healthcare solutions focused on orthopedic infection management strategies worldwide. By combining the innovative capabilities of GetSet Surgical with our existing product offerings, we are striving to create and become the premier choice for surgeons and their patients in the single-use, sterile packaged spinal procedure market.”
Ole Stoklund, founder and CEO of GetSet Surgical stated: “The integration of GetSet’s cutting-edge sterile packaged spine procedure kits with Demetra Holding’s robust portfolio and resources will significantly enhance our mutual commitment to minimizing infection risks and optimizing operational efficiencies in hospitals and the emerging ASC market.”
Global expansion and US market focus
As part of its expansion plans, Demetra Holding is prioritizing the introduction of GetSet’s products into the United States market. The newly established US Spine Division of Demetra’s portfolio company OsteoRemedies will manage the distribution of these products. This division will be headed by Ted Bird, an industry veteran recently appointed Vice President Spine Commercial.
The initial US product offerings will include GetSet’s GoPLF!™ Posterior Lateral Fusion system, already FDA approved. Introduction of GetSet's GoLIF!™ Lumbar Interbody Fusion system is anticipated to take place later this year following FDA 510(k) clearance which is pending. Additional systems already in development will be expedited by this new investment.
Integration into Demetra's global infrastructure
Beyond the US, Demetra Holding is committed to expanding GetSet Surgical’s innovative products across its global operations. Both the GoPLF!™ and GoLIF!™ systems are already CE-marked and available for distribution in European and other International markets. By leveraging Demetra’s extensive infrastructure, the integration of GetSet Surgical will expand the availability of advanced healthcare solutions in key global markets, with a focus on improving patient outcomes and driving efficiency in healthcare delivery worldwide.
About Demetra Holding SpA - Headquartered in Milan, Italy, Demetra Holding is dedicated to aggregating innovative healthcare companies that enhance lives through advanced products with a focus on infection prevention and control. For more information, visit www.demetraholding.com
About GetSet™ Surgical - Founded in 2016 in Switzerland, GetSet™ Surgical is transforming conventional spine surgery practices by providing sterile-packed, ready-to-use implants and instruments. More information can be found at www.getsetsurgical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227359973/en/
Contacts
For more information, contact:
Edelman - Press Office
Paola Maini - paola.maini@edelman.com
Elena Parodi - elena.parodi@edelman.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom